The incidence of cardiovascular and cerebrovascular complications in patients with uncontrolled hypertension

Cover Page

Cite item

Full Text

Abstract

Aim. To assess the incidence of cardiovascular and cerebrovascular events in patients with controlled and uncontrolled hypertension, controlled resistant and uncontrolled resistant hypertension, refractory hypertension, and probably resistant and probably refractory hypertension.

Materials and methods. A telephone call was made to 256 patients with hypertension included in the database to assess the incidence of cardiovascular and cerebrovascular diseases. All responding patients were divided into 7 groups according to the classification of hypertension based on the achievement/non-achievement of target blood pressure values and the number of drugs taken (controlled and uncontrolled hypertension, controlled resistant and uncontrolled resistant hypertension, refractory hypertension, and probably resistant and probably refractory hypertension). The target blood pressure was considered to be less than 140/90 mm Hg. Patients not adhering to medication were not included in the analysis.

Results. The group of controlled hypertension included 146 (57%) patients out of 256, controlled resistant hypertension – 36 (14%) patients, uncontrolled hypertension – 6 (2.3%) patients, resistant uncontrolled hypertension – 22 (8.6%) patients, refractory hypertension – 31 (12.1%) patients. The group of probably resistant hypertension – 6 (2.3%) patients, probably refractory hypertension – 9 (3.5%) patients. Of the 28 events that occurred, 6 were attributed to coronary artery disease (including 3 acute myocardial infarction and 2 coronary artery stenting), 3 strokes, 6 episodes of transient ischemic attack and 10 new cases of atrial fibrillation, and 2 patients had sudden cardiac death. Significantly more often, patients with refractory hypertension developed any event compared with patients with controlled (38.7% versus 3.4%; p=0.005) and resistant hypertension (38.7% versus 13.6%; p=0.04). Also, patients from the group of probably refractory hypertension were more likely to develop events than patients with controlled hypertension (33.3% versus 3.4%; p=0.045). Patients with probably refractory hypertension significantly more often had a stroke than patients with controlled hypertension (22.2% versus 0%; p<0.05), and patients with refractory hypertension significantly more often had a transient ischemic attack compared with patients from the group of controlled hypertension (12.9% versus 0.7%; p=0.03).

Conclusion. Patients with refractory and probably refractory hypertension are significantly more likely to develop cardiovascular and cerebrovascular complications than patients with controlled hypertension.

About the authors

Anastasiya R. Denisova

National Medical Research Center of Cardiology

Author for correspondence.
Email: nastya4358@gmail.com
ORCID iD: 0000-0003-2686-3026

врач-кардиолог 5-го клин. отд-ния (отд. гипертонии) Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

Tatyana D. Solntseva

National Medical Research Center of Cardiology

Email: nastya4358@gmail.com
ORCID iD: 0000-0002-7381-7818

клин. ординатор 5-го клин. отд-ния (отд. гипертонии) Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

Aihanum S. Zarmanbetova

National Medical Research Center of Cardiology

Email: nastya4358@gmail.com
ORCID iD: 0000-0002-7097-4391

клин. ординатор 5-го клин. отд-ния (отд. гипертонии) Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

Alina A. Tkacheva

National Medical Research Center of Cardiology

Email: nastya4358@gmail.com
ORCID iD: 0000-0002-5720-0279

клин. ординатор 5-го клин. отд-ния (отд. гипертонии) Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

Olga A. Sivakova

National Medical Research Center of Cardiology

Email: nastya4358@gmail.com
ORCID iD: 0000-0002-0060-095X

канд. мед. наук, зав. отд-нием, врач-кардиолог 5-го клин. отд-ния (отд. гипертонии) Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

Irina Е. Chazova

National Medical Research Center of Cardiology

Email: nastya4358@gmail.com
ORCID iD: 0000-0002-9822-4357

акад. РАН, д-р мед. наук, проф., зам. ген. дир. по научно-экспертной работе, рук. отд. гипертонии Института клинической кардиологии им. А.Л. Мясникова

Russian Federation, Moscow

References

  1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165-82. Erratum in: JAMA. 2017;317(6):648. doi: 10.1001/jama.2016.19043; PMID: 28097354
  2. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. doi: 10.26442/2075082X.2019.1.190179
  3. Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14 [Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (in Russian)]. doi: 10.15829/1728-8800-2014-4-4-14
  4. Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH–ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3):135-232. doi: 10.1080/08037050701461084; PMID: 17846925
  5. Aelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7-12.
  6. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. A novel phenotype of antihypertensive treatment failure. Hypertension. 2016;67:1085-92. doi: 10.1161/HYPERTENSIONAHA.116.06587
  7. Franco V, Mulatero P. Resistant or refractory hypertension: it is not just the of number of drugs. J Hypertens. 2021;39(3):589-91. doi: 10.1097/HJH.0000000000002814
  8. Данилов Н.М., Агаева Р.А., Матчин Ю.Г., и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии (РМОАГ) по применению радиочастотной денервации почечных артерий у пациентов с артериальной гипертонией. Системные гипертензии. 2020;17(4):7-18 [Danilov NM, Agaeva RA, Matchin UG, et al. Russian Medical Society on Arterial Hypertension (RMSAH) Consensus of Experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. Systemic Hypertension. 2020;17(4):7-18 (in Russian)]. doi: 10.26442/2075082X.2020.4.200398
  9. Аксенова А.В., Сивакова О.А., Блинова Н.В., и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив. 2021;93(9):1018-29 [Aksenova AV, Sivakova OA, Blinova NV, et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(9):1018-29 (in Russian)]. doi: 10.26442/00403660.2021.09.201007
  10. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635-42.
  11. Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8:405-13.
  12. Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622-32. doi: 10.1038/ki.2015.142; PMID: 25945406; PMCID: PMC4556588
  13. Van der Sande NGC, de Beus E, Bots ML, et al. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease. J Hypertens. 2018;36(1):143-50. doi: 10.1097/HJH.0000000000001494
  14. Денисова А.Р., Есаулова Т.Е., Солнцева Т.Д., и др. Особенности клиники и течения артериальной гипертонии у больных с ее различными формами. Системные гипертензии. 2021;18(3):140-6 [Denisova AR, Esaulova TE, Solntseva TD, et al. Clinical features and course of arterial hypertension in patients with its various forms. Systemic Hypertension. 2021;18(3):140-6 (in Russian)]. doi: 10.26442/2075082X.2021.3.200921
  15. Cardoso CRL, Salles GF. Refractory hypertension and risks of adverse cardiovascular events and mortality in patients with resistant hypertension: a prospective cohort study. J Am Heart Assoc. 2020;9:e017634. doi: 10.1161/JAHA.120.017634

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Distribution of patients by groups of arterial hypertension – AH (n=256), %.

Download (97KB)
3. Fig. 2. Distribution of complications in patients with AH of all types.

Download (68KB)

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies